Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the adult AIDS clinical trial group cardiovascular disease focus group

Clinical Infectious Diseases

Volumn 31, Issue 5, 2000, Pages 1216-1224

  Mayer, Kenneth H ^a   Dubé, Michael P ^a   Sprecher, Dennis ^b   Henry, W Keith ^c   Aberg, Judith A ^d   Torriani, Francesca J ^e   Hodis, Howard N ^f   Schouten, Jeffrey ^g   Levin, Jules ^h   Myers, Gary ⁱ   Zackin, Robert ^j   Nevin, Thomas ^k   Currier, Judith S ^l  

^a INDIANA UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Community Constituency Group Seattle ^*  (United States)

^h National AIDS Treatment Advocacy Project   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^k AIDS Clinical Trials Group Operations Center   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATORVASTATIN; CERIVASTATIN; EFAVIRENZ; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; ITRACONAZOLE; MEVINOLIN; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SIMVASTATIN; STATINE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DYSLIPIDEMIA; FLUSHING; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RHABDOMYOLYSIS; RISK FACTOR;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS;

EID: 0034457426     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317429     Document Type: Article

References (86)

1. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
2. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
3. The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS
4. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B
5. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection
6. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection
7. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex
8. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
9. Marked hyperlipidaemia on ritonavir therapy
10. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors
11. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
12. Significant increases in serum cholesterol are seen among HIV patients taking protease inhibitors
13. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
14. Incidence of and factors associated with the development of hypercholesterolemia and hyperglycemia in HIV-infected patients using a protease inhibitor
15. The incidence of hyperlipidaemia with protease inhibitors (PI)
16. Clinical investigation of the incidence and severity of elevated cholesterol (CH) and triglycerides (TG) in AIDS patients receiving protease inhibitor (PI) therapy
17. Screening for hyperglycemia and hyperlipidemia in HIV-infected persons receiving protease inhibitors
18. Investigation of protease inhibitor-associated hypercholesterolemia in a university-based HIV clinic
19. Change in weight, body composition, and serum lipids prior to and after initiation of protease inhibitors
20. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
21. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study
22. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients
23. Lipid elevations during non-nucleoside RTI (NNRTI) therapy: A cross-sectional analysis
24. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor-naive patients in year two of follow-up
25. Effect on ritonavir on lipids and post-heparin lipase activities in normal subjects
26. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
27. National Cholesterol Education Program: Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
28. Severe premature coronary artery disease with protease inhibitors
29. Vascular complications associated with use of HIV protease inhibitors
30. Vascular complications associated with use of HIV protease inhibitors
31. Vascular complications associated with use of HIV protease inhibitors
32. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
33. Effect of initiating indinavir therapy on glucose metabolism in HIV-infected patients: Results of minimal model analysis
34. Visceral abdominal-fat accumulation associated with use of indinavir
35. The mortality of rheumatoid arthritis
36. Cardiovascular mortality in rheumatoid arthritis: How harmful are corticosteroids?
37. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population
38. Risk factors for coronary artery disease in patients with systemic lupus erythematosus
39. Effects of cyclosporine therapy on plasma lipoprotein levels
40. Effect of pravastatin on outcomes after cardiac transplantation
41. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
42. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
43. Clinical, virological, and immunological benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy: 36-week follow-up
44. A prospective, open-label pilot trial of a maintenance nevirapine-containing regimen in patients with undetectable viral loads on protease inhibitor regimens for at least 6 months
45. Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz
46. Identification of fat redistribution/metabolic anomalies in a cohort treated by 2 NRTIs + 1 PI, and absence of significant modification following PI-substitution
47. Impact of switching from HIV-I protease inhibitors (PI) to efavirenz (EFV) in patients with lipodystrophy
48. Changes in visceral adipose tissue and blood lipids in persons reporting fat redistribution syndrome switched from PI therapy to efavirenz
49. Prospective follow-up of a PI substitution for efavirenz in patients with HIV-related lipodystrophy syndrome
50. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors (PI) to efavirenz (EFV)
51. A novel use of abacavir to simplify therapy in PI experienced patients successfully treated with HAART: CNA30017
52. Protease inhibitor class-sparing maintenance therapy with abacavir (ABC) + lamivudine (3TC) + zidovudine (ZDV) in patients with long-term suppression of HIV-1 RNA
53. Improvement of lipodystrophy in HIV-1 infected subjects switching from 2NRTI/PI to 2NRTI/Abacavir (French substudy, CNA30017)
54. Plasma triglyceride level is a risk factor for cardiovascular disease independent of HDL cholesterol level: A meta-analysis of population-based prospective studies
55. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
56. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and estrogen/progestin replacement study (HERS) research group
57. Cholesterol reduction yields clinical benefit. Impact of statin trials
58. Drug treatment of lipid disorders
59. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
60. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
61. Effects of itraconazole on the pharmacokinetics of atorvastatin
62. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
63. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
64. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
65. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors
66. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors
67. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: An exercise provocation test
68. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate
69. Heparin-releasable lipoprotein lipase activity is reduced in PI-associated hypertriglyceridemia
70. Are the decreased lipolytic enzyme activities responsible for the hypertriglyceridemia in PI-treated patients?
71. Increased Apo B synthesis and defective delipidation of triglyceride-rich VLDL are potential mechanisms of ART-associated dyslipidaemia
72. Mechanism of action of gemfibrozil on lipoprotein metabolism
73. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia
74. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease
75. Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat
76. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
77. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
78. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
79. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low HDL cholesterol levels, and desirable LDL cholesterol levels. HIT Investigators. Department of Veteran's Affairs HDL Intervention Trial
80. Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus
81. Increased B-cell secretory capacity as a mechanism for islet cell adaptation to nicotinic acid-induced insulin resistance
82. Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: Relation to indices of cytokine production
83. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus
84. Biological effects of omega-3 fatty acids in diabetes mellitus
85. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia
86. Comparison of statins in hypertriglyceridemia